|Bid||0.2100 x 0|
|Ask||0.2300 x 0|
|Day's Range||0.2150 - 0.2300|
|52 Week Range||0.1800 - 0.5300|
|Beta (5Y Monthly)||0.18|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec. 27, 2006|
|1y Target Est||N/A|
Using the services and expertise of Contract Research Organization, Roowin SA, Sirona scaled-up production to the multi-kilogram level. Sirona management is currently in advanced negotiations with Chinese producers regarding large scale manufacturing of TFC-1067 and expects to sign an agreement in this regard within the next quarter. Sirona also announces a successful attendance at BIO Digital, June 8-12, 2020.
Other projects at early stages of research and development include therapeutic compounds to treat urinary tract infections, Crohn's disease, anti-inflammatory drugs and anticancer drugs are now made public. "The anti-wrinkle program is progressing nicely with further studies beginning next week and the potential for a clinical trial in 2021", added Dr. Howard Verrico , CEO of Sirona Biochem.
After two months of extensive research, TFChem scientists have determined the proprietary platform technology can be applied to develop new antiviral compounds. The goal is to develop novel multi-target antiviral compounds, affecting different steps of the viral life cycle. Therapies to treat most viral infections are limited and the emergence of new viruses can greatly endanger society, as is currently the case with the pandemic caused by COVID-19, also known as Coronavirus or SARS-CoV-2.
Over the last several weeks, Sirona Biochem's management has been monitoring the recent increase in cases of Coronavirus (COVID-19), as we are sure many of you have. As an international organization, operating on three continents, Sirona has been one of the many companies affected by recent events.
Huaxipharm will co-develop on all steps to complete full commercialization of the products created by Sirona. This includes preclinical, clinical development, regulatory, commercial scale up and manufacturing for commercial applications of Sirona's compounds for indications mutually agreed upon in the definitive agreement.
It might be of some concern to shareholders to see the Sirona Biochem Corp. (CVE:SBM) share price down 17% in the last...
VANCOUVER , Feb. 14, 2020 /CNW/ - Sirona Biochem Corp. (SBM.V) (ZSB.F) (SRBCF) (the "Company") announces that it has changed its auditors from MNP LLP (the "Former Auditor") to DeVisser Gray LLP (the "Successor Auditor") effective January 27, 2020 and the board of directors of the Company appointed the Successor Auditor as the Company's auditor effective January 27, 2020 until the next Annual General Meeting of the Company. There were no reservations in the Former Auditor's audit reports for the relevant period, being the financial years ended October 31, 2018 and October 31, 2017 and any period subsequent to the most recently completed financial year for which an audit report was issued and preceding the resignation of the Former Auditor.
Sirona is now in preparation for the increased dose (0.4%) clinical study for its skin lightening compound TFC-1067. The HRIPT study was coordinated by Eurofins Dermscan in Poland (www.eurofins.com) and was executed by Eurofins EVIC Product Testing Romania under the direction of a clinical dermatologist.
The options, to purchase common shares in the capital of the Company at a price of $0.45 per common share, will be for periods ranging from 1 to 10 years. The options have been granted under the terms of the Company's stock option plan. Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology.